PsychedelicsEUROPE

💡Psychedelic Spotlight: Ibogaine💡 While comprehensive in many aspects, the EU's mental health strategy has yet to fully address the rising issue of addiction disorders. Ibogaine could potentially play a significant role in this context. Given the EU's commitment to improving mental health and addressing the addiction crisis, there is a clear need for more research and policy discussion around substances like Ibogaine. The EU should rigorously investigate its potential in treating addiction disorders, learning from best practices in other countries. For example, the recent allocation of $43 million in the state of Kentucky toward clinical research of Ibogaine is a major step in approaching the opioid crisis with innovative treatment.

Recently met with MEP @alexagiussaliba, co-chair of the new MEP Action Group for the Medical Use of Psychedelics. It's super important to discuss the overlaps between innovative therapies and key EU strategies (e.g. Comprehensive Approach to Mental Health, Pharmaceutical Strategy for Europe). One of the most effective ways to improve the well-being of Europeans.

💪Powerful words from MEP Alex Agius Saliba🇪🇺 During last week's event "Psychedelic Therapies: Learn Directly from Leading European Experts" which marked the launch of the MEP Action Group on the Medical Use of Psychedelics, MEP @alexagiussaliba delivered an inspiring speech, vividly outlining the motivations for establishing the group🚀

🎉It's happening! We helped set up the @Europarl_EN Action Group for the Medical Use of Psychedelics🌍🇪🇺. Thanks to the co-chairing MEPs @alexagiussaliba @Frederiqueries @vonpecka @sara_saracerdas @TomasZdechovsky and member MEPs @alviinaalametsa @JaroslawDuda @RobertBiedron @MaxovaRadka, Europeans gained a dedicated team that will promote access for innovative mental health care. 🧠💙 Exciting times ahead for improving mental well-being across the continent! Let's break barriers and prioritize mental health! Join our journey 💪✨ #MentalHealthMatters

MEPs and top experts discussing the potential of psychedelic therapies. Event co-organized by @psychedelicseurope just started in @europarl. Establishment of the MEP Action Group for the Medical Use of Psychedelics to be announced.

The final step of a long journey: The establishment of an MEP Advocacy Group for the Medical Use of Psychedelics is imminent.

Bringing together policymakers across party lines with high-level experts (scientists, regulators) is a major milestone towards establishing an MEP advocacy group for the medical use of psychedelics.

Let's not forget how effective psychedelic medicines can be.

💊EMA Chief Medical Officer acknowledges difficulties in EU approval process for psychedelics. Globally, many promising phase I-III psychedelic trials exist, most outside EU. Happy to see EU key players taking note of this imbalance. Hope this will spill over into member states.

Great news! Spain prioritizes mental health for the upcoming EU Council Presidency. Starting this summer, medicinal use of psychedelics shall be put on the spotlight of Brussels discussions. A science-based comprehensive EU mental health strategy must include psychedelic therapy.

@amaiou @neurodelia @imperialcollege What an interesting read! Thanks @amaiou !

We applaud👏 the statement by @butlen_ducuing from @EMA_News🇪🇺 on psychedelics🍄: “There are some trials indicating some promising effects, but we really need to understand better how they work and how they can be safely administrated to patients.” 🔬🧠

❗Ayahuasca could treat depression.❗ DMT’s ability to make brain activity🧠 more fluid is thought to support the promising results🔬 from early clinical trials where patients were given DMT in combination with psychotherapy to treat depression.👏 theguardian.com/science/2023/m…

As MDMA inches closer to becoming an approved medicine in the US it is important to understand how the therapies👩‍⚕️👨🏽‍⚕️ can be combined with MDMA effects on body and brain🧠 to support healing. The @EU_Commission🇪🇺 should follow closely these developments. businessinsider.com/what-is-mdma-m…

We are glad to hear from @SKyriakidesEU that the Comprehensive approach to mental health expected in June 2023 is just a starting point.✅ New initiatives on mental health🧠 should follow, including the much-needed innovative🔬 treatments for the benefit of EU citizens.

Feedback to the @EU_Commission🇪🇺 call for evidence on EU comprehensive approach to mental health submitted.✅ The EU policy-makers should listen to the scientific findings🔬 on the therapeutical potential of psychedelics when developing EU initiative on mental health.🧠

❗Breaking news❗ Australia is reclassifying MDMA and psilocybin to allow psychiatrists to prescribe these substances for treatments of depression and PTSD. Psychedelic therapies are becoming legal and the @EU_Commission🇪🇺 should be aware of this. tga.gov.au/news/media-rel…

Time to speak up❗🔊 @EU_Commission 🇪🇺 seeks feedback ahead of the upcoming comprehensive approach to mental🧠 health. We will emphasize evidence on psychedelics and their compassionate use.🌟 Let us know for advice on how to make use of this opportunity for your project!

According to @EU_Commission🇪🇺 a comprehensive approach to mental health🧠 is to be out at the end of June.👏 We will continue in our efforts to secure that the medicinal use of psychedelics will be an integral part of it. Let’s work together!🤝 ec.europa.eu/transparency/d…